Coverage
-
June 19, 2015
A New Jersey federal judge denied Jazz Pharmaceuticals Inc.'s appeal of an order allowing Roxane Laboratories Inc. to amend its invalidity and noninfringement arguments in a suit over a planned generic of Jazz's narcolepsy drug Xyrem, saying Friday the amendments are timely.
1 other articles on this case.
View all »